Quetiapine use in adults in the community: A population-based study in Alberta, Canada

BMJ Open

Volumn 6, Issue 3, 2016, Pages

  Duncan, Diane ^a   Cooke, Lara ^a,b   Symonds, Chris ^a   Gardner, David ^c   Pringsheim, Tamara ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CANADA; COMMUNITY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; NEUROSIS; PARTICIPATORY RESEARCH; PHYSICIAN; PRESCRIPTION; RECIPIENT; REGISTER; SLEEP DISORDER; ALBERTA; ANXIETY DISORDERS; DEPRESSIVE DISORDER; MIDDLE AGED; SEX RATIO; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; ALBERTA; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUETIAPINE FUMARATE; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84962273629     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010861     Document Type: Article

References (18)

1. Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open 2014;2:E225-32.
2. Pringsheim T, Lam D, Patten SB. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents, 2005-2009. J Child Adolesc Psychopharmacol 2011;21:1-8.
3. Alessi-Severini S, Biscontri RG, Collins DM, et al. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry 2012;57:52-8.
4. Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second generation antipsychotic use in children. Drug Saf 2011;34:651-68.
5. Gardner DM, Teehan MD. Antipsychotics and their side effects. Cambridge: Cambridge University Press, 2010.
6. Pringsheim T, Panagiotopoulos C, Davidson J, et al. Evidence based recommendations for monitoring safety of second generation antipsychotics in children and youth. Pediatr Child Health 2011;16:581-9.
7. Patten SB, Williams JVA, Lavorato DH, et al. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can J Psychiatry 2015;60:23-30.
8. Overview of Administrative Health Datasets2015 2015. 01.13. http://www.health.alberta.ca/documents/Research-Health-Datasets.pdf
9. Health Canada Drug Product Database Data Extract Files2015 2015. 01.13. http://hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/dpd-bdpp-data-extract-eng.php
10. Alberta Health Claims Assessment Alberta Health Diagnostic Codes2015 2015. 01.13. http://www.health.alberta.ca/documents/Diagnostic-Code-ICD-9.pdf
11. Pringsheim T, Gardner D, Patten SB. Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks? BMJ 2015;350:h569.
12. Depping AM, Komossa K, Kissling W, et al. Second generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010; (12): CD008120.
13. Kuehn B. FDA panel issues mixed decision on quetiapine in depression and anxiety. JAMA 2009;301:2081-2.
14. Allied Health Practitioner's Resource Guide2015 2015. 01.13. http://www.health.alberta.ca/documents/Allied-Practitioners-Guide-2014.pdf
15. Cunningham CT, Cai P, Topps D, et al. Mining rich health data from Canadian physician claims: features and face validity. BMC Res Notes 2014;7:682.
16. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Br J Psychiatry 2012;200:393-8.
17. Marston L, Nazareth I, Petersen I, et al. Prescribing antipsychotics in UK primary care: a cohort study. BMJ Open 2014;4:e006135.
18. Citrome L, Kalsekar I, Guo Z, et al. Diagnoses associated with use of atypical antipsychotic in a commercial health plan: a claims database analysis. Clin Ther 2013;35:1867-75.